Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that is used for the treatment of (paediatric) hypertension, heart failure and chronic kidney diseases. Because its disposition, efficacy and safety differs across the paediatric continuum, data from adults cannot be automatically extrapolated to children. This review highlights paediatric enalapril pharmacokinetic data and demonstrates that these are inadequate to support with certainty an age-related effect on enalapril/enalaprilat pharmacokinetics. In addition, our review shows that evidence to support effective and safe prescribing of enalapril in children is limited, especially in young children and heart failure patients; studies in these groups are either absent or show conflicting results. We provide explanations for observed differences between age groups and indications, and describe areas for future research.

Additional Metadata
Persistent URL dx.doi.org/10.1016/j.drudis.2020.08.005, hdl.handle.net/1765/130057
Journal Drug Discovery Today
Citation
Smeets, N.J.L. (Nori J.L.), Schreuder, M.F, Dalinghaus, M, Male, C, Lagler, F.B. (Florian B.), Walsh, J. (Jennifer), … de Wildt, S.N. (2020). Pharmacology of enalapril in children: a review. Drug Discovery Today. doi:10.1016/j.drudis.2020.08.005